Mapp Biopharmaceutical
Press Inquiries
  • About Us
  • Product Development
  • News
    • In the News
    • Press Releases
  • Publications
  • Job Openings
  • Contact Us
BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin

by Mapp Admin | Jan 13, 2021 | Press Releases

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin BARDA and its partner Mapp Biopharmaceutical Inc. will explore the potential of a new monoclonal antibody (mAb) based therapeutic for Botulinum Neurotoxin...

read more
MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure

MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure

by Mapp Admin | Jun 11, 2019 | Press Releases

MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure June 11, 2019 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded an advanced research and...

read more
Experimental antibody ‘cocktail’ protects animals from three deadly Ebola viruses

Experimental antibody ‘cocktail’ protects animals from three deadly Ebola viruses

by Mapp Admin | Jan 11, 2019 | Press Releases

Public Release

read more
MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure

MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure

by Mapp Admin | Sep 28, 2018 | Press Releases

MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure September 28, 2018 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded a contract (HHSO100201800024C) of $14.8 million with options for...

read more

Archives

  • January 2021
  • June 2019
  • January 2019
  • September 2018

Categories

  • Press Releases

Recent News

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin

Jan 13, 2021

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin BARDA and its partner Mapp Biopharmaceutical Inc. will explore the potential of a new monoclonal antibody (mAb) based therapeutic for Botulinum Neurotoxin...

MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure

Jun 11, 2019

MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure June 11, 2019 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded an advanced research and...

Additional Information

  • FCOI Policy
  • Purchase Order Terms and Conditions
  • Pay Transparency Nondiscrimination Provision
  • Equal Employment Opportunity is the Law
  • Institutional Biosafety Committee (NIH)
  • Employment of Individuals with Disabilities and Protected Veterans
  • Equal Employment Opportunity and Affirmative Action Policy Statement
  • Expanded Access Policy
Jobs Opportunities

© 2017-2022 Mapp Biopharmaceutical. All Rights Reserved.